Connective tissue panniculitis: lupus panniculitis, dermatomyositis, morphea/scleroderma.

Abstract

Panniculitis is an uncommon cutaneous manifestation of connective tissue diseases. Our discussion will include panniculitis occurring in the setting of lupus erythematosus, dermatomyositis, and scleroderma/morphea. These subtypes of panniculitis are unified by an active inflammatory stage of the disease that can progress to develop scarring, atrophy, and calcifications. Treatment is most effective if initiated during the active phase of the disease and often requires systemic therapy because of the location of the inflammation. Antimalarials are the initial treatment of choice for most cases of lupus erythematosus panniculitis, whereas corticosteroids in combination with other steroid-sparing immunosuppressive agents are the first-line treatment for panniculitis in patients with dermatomyositis. The appropriate treatment for panniculitis in the setting of morphea/scleroderma varies based on clinical severity.

• Authors: Christopher B Hansen, Jeffrey P Callen
• Journal: Dermatologic therapy (Dermatol Ther) 2010 Jul-Aug Vol. 23 Issue 4 Pg. 341-9 ISSN: 1529-8019 [Electronic] United States
• PMID: 20666821 (Publication Type: Journal Article)

Chemical References

• Antimalarials
• Glucocorticoids
• Immunosuppressive Agents

Topics

• Antimalarials (administration & dosage, adverse effects, therapeutic use)
• Dermatomyositis (drug therapy, physiopathology)
• Glucocorticoids (administration & dosage, adverse effects, therapeutic use)
• Humans
• Immunosuppressive Agents (administration & dosage, adverse effects, therapeutic use)
• Inflammation (drug therapy, etiology, physiopathology)
• Panniculitis, Lupus Erythematosus (drug therapy, physiopathology)
• Scleroderma, Localized (drug therapy, physiopathology)
• Severity of Illness Index